Meet the pitching companies
Silengenics
By Laura Matonog, CEO & Co-Founder
Silengenics is a biotech company developing proprietary gene silencing oligonucleotide therapeutics and building a first-in-class gene-silencing platform, targeting both cancer and metabolic disease. Our technologies have the potential to reshape treatment where current therapies fall short, positioning it for high-value pharma partnerships and eventual first-in-human trials around 2028.
Hemastatx
By Kevin Hollevoet, CEO & Co-Founder
Hemastatx develops transformative therapies for severe bleeding disorders. Lead program HMX-001 is a first-in-class antibody for von Willebrand Factor disorders, targeting ADAMTS13. Supported by robust preclinical data and broad patent coverage, it offers a pipeline-in-a-product with blockbuster potential.
Quantum BioVenture Studio
By Florence Bosco, CEO & Head of R&D
Quantum BioVenture Studio is a Belgium-based pioneering TechBio venture builder leveraging bioML and iPSC-derived multiomics to accelerate novel target discovery. Our science is rooted in cutting-edge research from UCLouvain’s de Duve Institute and Vlaams Institute voor Biotechnology’s VIB.AI. Our first venture focuses on Stargardt Disease, a juvenile inherited retinal disease, with expansion potential to dry AMD.
Enodia Therapeutics
By Yves Ribeill, CEO
Enodia Therapeutics is advancing a targeted protein degradation (TPD) platform with best-in-class small-molecule inhibitors of the Sec61 translocon channel. Unlocking undruggable proteins in the secretory pathway, we open new therapeutic opportunities in inflammation, autoimmune diseases and oncology.
Regel Therapeutics
By Jordane Dimidschstein, President & COO
Regel Therapeutics is developing precision medicines with its Targeted EpiEditing platform to restore gene expression exclusively in disease-affected cells. Lead programs in Dravet and SCN2A are advancing toward the clinic, supported by a $60M Series A targeted to close in Q4 2025.
Dendrogenix
By Philippe Lefebvre, Founder & CSO
DENDROGENIX is a biopharmaceutical company based in Liège dedicated to developing NCE (New Chemical Entities) named “Dendrogenins” till early clinical development to address important unmet medical needs in the field of neurological disorders with a first therapeutic indication on hearing loss, and more specifically in presbycusis indication.
Theratrame
By Francesca Rapino, CEO
THERAtRAME develops TTR-001, a first-in-class tRNA modulator with a dual mode of action: inducing intrinsic tumor cell death while boosting immune attack. This disruptive approach eliminates cancer’s adaptive survival routes, backed by a tRNA-centric discovery platform and a growing pipeline of programs in development.
Santero Therapeutics
By Cedric Govaerts, CEO
Santero is developing innovative solution to combat the emerging threat of resistant bacterial infections. After successfully demonstrating the POC of our novel MoA, we are developing multiple chemical series to tackle both Gram negative and Gram positive pathogens